Join experts for a conversation on recent progress in cancer research, including novel treatments, experimental therapies, and drug development.
Starting off the conversation, Dr. David Bunka presents specific case studies for prostate cancer, multiple myeloma and chronic myelomonocytic leukaemia, highlighting the ability of Optimer technology to deliver novel targeted therapeutics for cancer treatment. Optimer binders are small, highly target specific oligonucleotide-based affinity binders. The Optimer platform offers the ability to develop specific binders targeted to a specific biomarker or to an oncological cell phenotype without the need for known biomarkers. Optimer therapeutics are enabling new strategies in cancer treatment, including the targeted delivery of diverse payloads to cancer cells for precision chemotherapy, or gene therapy approaches.
Dr. Cathie Miller discusses how archived tissues contain valuable information for clinical research. For over thirty years, BioIVT has worked to expand the characterization of their archived tissues. BioIVT offers complete NGS project management that ensures success. In this presentation, Dr. Miller reviews BioIVT's comprehensive process, their strengths in sample collection through library prep, their in-house and validated partnership capabilities and how BioIVT elevates science.
Finally, Henry Sebesta introduces KromaTiD's proprietary technology, Directional Genomic Hybridization, as an analytical solution for gene & cell therapy oncology treatments. Specifically, Mr. Sebesta addresses what Directional Genomic Hybridization is, how it works, and how it can be used to monitor highly important clinical safety metrics including therapeutic vector integration, and genome wide structural rearrangement events.
Presenters
Cathie G. Miller
With a career that spans over 20 years at the bench, as well as a Director and a Global Product Manager, all involving the use of biospecimens in the fields of cancer, immunology and virology, Cathie is now Senior Director of Product Marketing, Personalized Medicine, at BioIVT.
David Bunka
David has spent nearly 20 years developing nucleic acid aptamers against a wide variety of targets including small molecules, disease-associated proteins, several cancer-associated cell-lines, viruses and tissue biopsies. This work has been facilitated through the use of high-throughput, automated aptamer selection methods.
Henry Sebesta
Henry Sebesta is a dedicated life sciences industry professional with years of experience in gene therapy product and business development.
Sponsor
BioIVT
Aptamer Group
KromaTiD, Inc.
Content Partners
Scientist.com
Scientist.com is the world’s largest and first platform built for the intricacies of scientific outsourcing.
We help pharmaceutical and biotechnology organizations discover, engage, manage, and scale relationships with the providers that support every stage of the pipeline—from discovery and preclinical research to clinical development, manufacturing, medical affairs, and commercialization. Through a centralized platform, organizations can access a global network of 6,000+ providers, streamline sourcing and procurement workflows, maintain compliance, manage supplier relationships, and leverage data-driven insights to make faster, more informed decisions.
Today, Scientist.com supports more than 130 life science organizations, including 24 of the world's top 30 pharmaceutical companies, helping teams reduce operational complexity, accelerate timelines, and bring innovations to patients faster. Our mission is to make it possible to cure all human disease by 2050.
HealthEconomics.com
HealthEconomics.com is the world’s largest Connected Community™ for Value, Evidence and Access in the life sciences industry.
HealthEconomics.com provides a single global link to the health economic and outcomes research (HEOR), real-world evidence (RWE), and Market Access (MA) stakeholder communities. Since 1993, we have provided unparalleled access to drive business, improve knowledge, and connect researchers and payer decision-makers world-wide.
Our 27,000 engaged readers rely on HealthEconomics.com as the most reliable, credible and curated digital hub for the latest news, insights, educational opportunities, and industry benchmarks in HEOR, RWE and MA. Our advertisers, numbering more than 500 with a 91% retention rate, depend upon HealthEconomics.com for best-in-class global brand awareness and business development solutions. Our aim is to connect people with expert-driven content and resources — all in one place — with the corporate mission to advance communication about healthcare value.
